UROLOGY VOLUME IV, JULY TO DECEMBER 1974

Pages	*Issue*
1 – 122	July
123 – 234	August
235 – 366	September
367 – 498	October
499 – 634	November
635 – 792	December

AUTHOR INDEX

Ablin, R. J., 107, 770
Aguilo, J., 488
Albers, D. D., 254
Albert, P., 229
Albert, P. S., 190, 307
Alfrey, A. C., 5
Al-Ghorab, M. M., 114
Allen, J. S., 271
Amelar, R. D., 495
Anderson, C. B., 607
Anderson, E. E., 669
Andrus, C., 378
Arcadi, J. A., 105
Armbruster, K., 709
Arnold, S. J., 145, 467
Arthur, K., 571
Awad, S. A., 18

Babson, A., 467
Bagley, D. H., 623
Bair, E. D., 734
Banowsky, L. H., 643, 650, 656
Bartone, F. F., 182
Baskin, A. M., 728
Baum, N. H., 581
Beasley, R. M., 623
Bensimon, H., 476
Berry, J. V., 209
Berson, M., 232, 233
Bias, H. I., 254
Birkhoff, J. D., 557
Bissada, N. K., 596, 674
Blackard C. E., 44, 69, 336
Blanc, W. A., 193
Block, N. L., 174
Bloomberg, S. D., 193
Bogash, M., 509
Bokinsky, G., 37
Borden, T. A., 734
Borski, A. A., 332
Bottaccini, M. R., 693
Bourdeau, G. V., 209
Bradley, W. E., 767
Brannan, W., 392
Braun, W. E., 643, 650, 656
Broecker, B., 37
Brosman, S., 129
Brown, J., 622
Bruce, A. W., 18
Bruns, G. R., 770
Bryson, M. F., 378
Burger, R., 40, 581
Burros, H. M., 155
Bush, I. M., 107, 770

Campbell, G. S., 338
Carlton, C. E., Jr., 581, 722
Carrion, H. M., 525, 681
Casali, R., 384
Catalona, W. J., 100, 287
Cates, J. L., 509
Cattolica, E. V., 397, 726
Chalbaud, R. A., 454
Chen, F. H., 348
Chesley, A. E., 450
Chrenka, B., 660
Chretien, P. B., 100
Cid, E., 230
Cochran, J. S., 367
Cockett, A. T. K., 378
Cohen, M., 229, 763
Cohen, R. L., 603
Collins, H. T., 392
Colodny, A. H., 357
Corica, A. P., 443
Correa, R. J., Jr., 605
Corriere, J. N., Jr., 27, 267
Cosgrove, M. D., 1, 186
Cromie, W. J., 27
Culp, D. A., 431
Cummings, K. B., 605
Cummings, N. B., 624

Dahl, D. S., 590
David, H. S., 463
Davis, J. E., 190, 307
Dees, J. E., 669
deKernion, J. B., 63
Desai, S. G., 598
DeWolf, W. C., 44
Dodson, A. I., Jr., 713
Doroshow, L. W., 346
Downie, J. W., 18
Downs, R. A., 519
Droller, M. J., 439
Dubin, L., 495
Duckett, J. W., Jr., 577, 720
Duncan, J. G., 274
Dziadiw, R., 715

Ehrlich, R. M., 193
El Bolkainy, M. N., 407
El Sebai, I., 407
Elson, E. C., 214
Emery, C. B., 201
Ernst, C. B., 598
Evans, A. T., 402

Fair, W. R., 540
Farrell, R. M., 51
Felderman, E. S., 341
Filly, R. A., 540
Firlit, C. F., 709
Flocks, R. H., 431
Ford, M. L., 95
Frank, I. N., 378
Francis, J., 650
Frantz, A. G., 557
Freed, S. Z., 92
Freeman, R. B., 378
Frensilli, F. J., 732
Fried, F. A., 677
Friedland, G. W., 315, 439, 540
Furlow, W. L., 488

Gadbois, W. F., 720
Gaeta, J., 414
Gaffney, C. M., 446
Gawande, A. S., 319

Ghoneim, M. A., 278, 407
Gibbons, R. P., 605
Gilbert, E. C., 732
Gilday, D., 665
Gillies, R. R., 209
Ginsburg, A., 145, 467
Gittes, R. F., 473
Gleason, D. M., 693
Glenn, J. F., 481
Goldstein, A. M. B., 201, 459
Gonzalez, R., 336
Gordon, M. E., 350
Gottesman, J. E., 311
Govan, D. E., 540
Grabstald, H., 571
Graham, J. B., 585
Greene, W. A., 378
Gregory, J. G., 27
Grimes, J. H., 669
Guinan, P. D., 107, 770
Gursel, E. O., 220

Hagerdorn, P., 773
Haleem, S. A., 92
Halvorson, H. C., 254
Hanafy, H. M., 85, 114, 261
Harrison, R. H., 121
Hausman, M. S., 129
Hawtrey, C. E., 431
Herman, J. R., 72-E, 173, 207-G, 235-J, 350-C, 367-BB, 496-A, 628
Herr, H. W., 57
Hertel, E., 13
Hewitt, C. B., 643
Hodges, C. V., 532
Holmes, J. H., 5
Holt, S. A., 322
Homsy, Y. L., 135
Howard, D., 361, 627
Husberg, B., 703
Husk, M., 297

Ignatoff, J. M., 585
Immergut, M. A., 732

Jacobowitz, D. M., 27
Jaksy, J., 174
Jaques, P. F., 544
Javadpour, N., 97
Jeffs, R., 665
Jindal, S. J., 209
Johanson, K-E., 514
Johnson, C. F., 722
Johnson, D. E., 454, 567
Jonas, U., 421
Jones, A., 741
Jones, L. W., 499
Jones, W. G., 186, 459
Josem, M., 231, 360, 772

Kaany, E., 343
Kadivar, R., 257
Kaldahl, P. E., 254
Kallet, S., 774
Kamat, M. H., 319, 504
Karafin, L., 635
Karp, J., 212
Kaufman, J. J., 140, 241
Kaufman, J. M., 728
Keitzer, W. A., 95, 271
Kelley, C. D., 571
Kendall, A. R., 635
Khadilkar, M. C., 450
Khang, C. S., 360
Kim, H., 182
King, L. R., 709
Kinkhabwala, M., 715
Kishev, S. V., 302
Kiviat, M. D., 601
Koontz, W. W., Jr., 713
Koziol, I., 456

Laferte, R. O., 162
LaJoie, W. J., 186
LaRocque, M. A., 1
Lattimer, J. K., 73, 557, 688
Lawson, R. K., 532
Lazarus, B., 230
Leadbetter, G. W., Jr., 623
Lebowitz, R. L., 357
Levey, S. H., 361, 362, 627
Licker, K., 492
Lien, W. M., 121
Linke, C. A., 378
Linke, C. L., 378
Lipshultz, L. I., 267
Litvak, A. S., 748
Lucey, D. T., 677
Lufkin, E. G., 5
Lutzeyer, W., 613
Lynne, C. M., 525, 603
Lyon, R. P., 435
Lywood, D. W., 18

Madduri, S., 504
Magnusson, M. O., 643, 650, 656
Mahmood, P., 361
Mahony, D. T., 162
Malik, I. K., 402
Malkin, R. B., 713
Mansour, M. A., 407
Marden, H. E., Jr., 443
Mark, L. K., 706
Marks, L. S., 140
Marshall, S., 225, 435
Marshall, V. F., 51
Martin, D. C., 57
Mason, J. T., 605
May, A. G., 378
McCullough, D. L., 112, 235
McGinnis, T. B., 596

McGuire, E. J., 728
McKay, I., 274
McLaughlin, A. P., III, 112, 214, 473
McRoberts, J. W., 748
Meares, E. M., Jr., 560
Megalli, M. R., 73, 220
Melchior, H., 613
Merin, R. G., 378
Merkel, F. K., 709
Merrill, D. C., 495, 574, 761
Merrin, C. E., 198, 283
Miller, J., 384
Milsten, R., 731
Mininberg, D. T., 307
Mitchell, D. S., 244
Mittelman, A., 283
Mittemeyer, B. T., 332
Montie, J. E., 656
Moore, R. H., 414
Morales, P., 514
Morgenlander, H. L., 686
Morneau, J. E., 567
Morrow, J. W., 201
Mount, B. M., 297, 741
Mulholland, S. G., 577
Mulkey, A. P., Jr., 426
Murdock, M. I., 60
Murphy, G. P., 283, 414

Najarian, J. S., 384
Neft, L. G., 761
Nelson, R. P., 574
Neter, E., 198
Neu, H. C., 193
Niendorf, D. C., 764

Ochsner, M. G., 392
Onofrio, R., 459
Orkin, L. A., 80

Pabico, R. C., 378
Palmer, J. M., 764
Parker, D. A., 90
Patil, U. B., 715, 737
Patterson, A., 741
Paul, J., 772
Pergament, M., 336
Persky, L., 63, 228
Perrin, E. V., 660
Persky, L., 660
Peter, E. T., 734
Peterson, D. D., 677
Peterson, L. J., 329, 669
Peterson, N. E., 322
Petritsch, P. H., 241
Pfister, R. R., 703
Philipps, E., 764
Pieretti, R., 665
Pinzus, T., 33

Plaine, L., 514
Politano, V. A., 603, 681
Pollack, H. M., 509, 623, 635
Pond, H. S., III, 392
Pontes, J. E., 109
Potvin, C., 100
Powell, N. B., 722
Puchner, P. J., 33

Raezer, D. M., 577
Ramos, C. M., 334
Rao, K. G., 204
Rathert, P., 613
Rattazzi, L. C., 384
Razvi, M., 107
Redman, J. F., 338, 596, 674, 739
Reeve, H. R., 329
Rege, P. R., 402
Reid, E. C., 135
Reilly, R. J., 693
Remigio, P. A., 334
Renert, W., 90
Robbins, J. S., III, 332
Roberts, J. A., 475
Rodgers, R., 44
Rogoff, E., 571
Rountree, G. A., 338
Roy, J. B., 494, 584
Rudin, L. J., 73
Rudy, S. M., 593

Saad, S. M., 85, 114, 261
Sacks, S. A., 241
Sadoughi, N., 107
Salerno, R. G., 190
Sankaran, R., 450
Schiff, M., Jr., 389
Schmidt, J. D., 431
Schoenfeld, L., 681
Scott, F. B., 767
Scott, M. P., Jr., 435
Scott, R., Jr., 223, 274
Scriber, L. J., 674
Seebode, J. J., 319, 504
Seim, S. K., 709
Selikowitz, S. M., 60
Shah, M. S., 212
Shelor, W. C., Jr., 550
Sherif, M., 407
Shopfner, C. E., 123
Shoukry, I., 278
Siegal, D. F., 643
Siegel, W. H., 411
Silber, I., 57
Simmons, R. L., 384
Sinclair, J., 274
Smith, A. M., 325
Smith, J. P., 739
Smith, R. B., 140, 248
Soliropoulos, A., 688
Soloway, M. S., 63
Sözer, I. T., 217
Spitzer, A. L., 448
Spjut, H. J., 40
Stables, D. P., 448
Stadalnik, R. C., 244
Stamey, T. A., 315, 439
Stein, J. J., 717
Stengel, J. N., 341
Stewart, B. H., 643
Straffon, R. A., 643
Strong, D. W., 623
Sullivan, M. J., 244
Summers, J. L., 95, 271
Surgalla, M. J., 198
Swick, M., 750
Symington, J. W., 608

Tabatabai, M., 257
Talley, T. E., 378
Tanagho, E. A., 421, 593
Tannenbaum, M., 33, 325, 354, 485, 617, 758
Tarpley, J., 100
Tessler, A. N., 174, 226, 352, 360, 494, 626, 772
Texter, J. H., Jr., 37
Thomas, A., 626, 772
Thurm, J., 231, 233, 774
Timm, G. W., 767
Tomashefsky, P., 33
Trucksess, M. E., 5
Tucker, A., 660

Ufferman, R. C., 378
Ullman, J. C., 212
Uson, A., 688

Vanderwerf, B. A., 525
Varkarakis, M. J., 414
Veenema, R. J., 33, 220
Viprakasit, D., 325
von Buedingen, R. P., 228, 717

Wainscott, P., 90
Wajsman, Z., 198
Walther, A. H., 494
Ward, J. N., 463
Warner, R. S., 229, 628
Washio, H., 463
Wayland, J. S., 601
Wein, A. J., 27
Weinerth, J. L., 228, 329
Weir, J., 544
Weiss, R. M., 389
Welch, M. J., Jr., 431
Welvaart, K., 283
Wendel, R. G., 402
Werner, S. L., 343
Wettlaufer, J. N., 293
Whittaker, J. R., 92
Wilkerson, J. E., 95
Williams, R. D., 69
Wilson, J. M., 248
Wise, G. J., 686
Witherington, R., 426, 550
Woodhead, D. M., 248

Yakub, Y. N., 378
Yalla, S. V., 155, 577
Yuvienco, F. P., 231

Zamora, D., 341
Zorgniotti, A. W., 363, 496, 629

SUBJECT INDEX

Abscess and fibrosis, retroperitoneal, 92
Abstracts, 229, 360, 626, 772
Acupuncture needle in bladder, 584
Adenocarcinoma
  mucus-producing, of renal pelvis, 488
  renal, 334
  in sigmoid kidney, 713
  of tongue and bladder metastasis, 454
Adenoma, nephrogenic, of bladder, 343
Adrenal cysts, 248
Aneurysm, renal artery, 532
Angiomyolipoma, renal, 235
Arterial collaterals in arteriovenous fistula, 715
Artifact, urologic, 485
Autotransplantation in renal salvage, 703
Avulsion of spermatic cord, 596

Bacteremia following renal transplant, 198
Bilharzial ureteritis cystica, 261
Biopsy, open renal, 182
Bladder
  atonic, 544
  cancer, 63
  chemotherapy in, 33
  carcinoma, 129
    extravasation from, 336
  chemical sympathectomy of, 27
  diverticula, 494
    carcinoma in, 411
  enlargement, 135
  flap rotation in repair of vesicovaginal fistula, 109
  foreign body in, 584
  function, evaluation of, 267
  large-capacity, 544
  metastasis from adenocarcinoma of tongue, 454
  nephrogenic adenoma of, 343
  neurogenic, 57, 95
    and regional ileitis, 593
  pathologic; electromyography in, 186
  rectal, with perineal colostomy, 278
  residual urine in, 737
  rupture of, 426
  tumor, 407, 414
    implant, 334
Blue nevus and epithelial melanosis, 617
Bone pain, relief of, with levodopa, 107
Book reviews
  Handbook of Urinalysis and Urinary Sediment (Kurtzman and Rogers), 629
  Living or Dying: Adaptation to Hemodialysis (Levy), 629
  The Urologic Clinics of North America: Neurogenic Bladder (Lapides), 364
  Urologic Endoscopic Procedures (Morel and Wise), 629

Calculi
  in children, 51
  giant prostatic, 319
  renal, 13
    nephroscope and Water-Pik for, 605
  ureteral, and creatine phosphokinase, 254
Calyceal compression, 244
Cancer
  of bladder, chemotherapy in, 33
  immunostaging of patients with, 770
  penile, radiation therapy of, 571
  prostatic, 107
    cryosurgery in, 220
    with paraplegia and paraparesis, 431
Candicidin in prostatic hypertrophy, 80, 494
Candidiasis, renal, and transitional cell carcinoma, 332
Carcinoma
  bilateral, of ureter, 217
  in bladder diverticula, 411
    extravasation from, 336
  metastatic, of prostate, 90
  prostatic, 354, 485
    cyrosurgery for, 499
    5-fluorouracil in, 287
  renal, 129, 514
    pelvis and ureter, 392
    pseudometastasis to liver in, 764
  squamous-cell, of bladder, 407
    of penis, 69
  stage D prostatic, 283
  transitional cell, 63
    and candidiasis, 332
  ureteral, 40
  of urinary tract, 174
  verrucose, of bladder, 407
Catheter dilatation for urethral stricture, 504
Children
  screening of, for urinary disease, 271
  urolithiasis in, 51
  uroradiologic evaluation in, 123
Chordee, cutaneous, 293
Circumcision-associated diabetes, 60
Coccidioidomycosis of prostate and epididymis, 311
Cock's instrument for tapping bladder, 350-C
Conduit and regional compliance of urethra, 155
Creatine phosphokinase, elevated, and ureteral calculi, 254
Cryosurgery
  perineal, 623
  in prostatic cancer, 220, 499
Cyst, Gartner's duct, and renal agenesis, 720
Cystitis
  emphysematosa, clostridial, 601
  interstitial, 135
Cystometrogram and fatal air embolism, 95

Cystometry and embolism, 494
Cysts
adrenal, 248
intrarenal peripelvic, 514
renal, 5

De Rigal's stone-holder perforator, 235-J
Death and dying, attitudes in hospital, 741
Diabetes
and circumcision, 60
insipidus, nephrogenic, 581
Diphallus, 688
Diversion, urinary, 278
Diethylstilbestrol diphosphate in prostatic cancer, 431
Donor organs in renal transplantation, 643
Drugs, sympathomimetic, effect of on bladder, 18
Dysplasia and renal duplication, 660

Ectopia of seminal vesicle, 322
Editorials
Plea for grading vesicoureteric reflux, 357
New section on uropathology, 358
"Immunostaging" patients with malignant disease, 270
New section on neurourology, 270
Education and recertification, 481
Egyptian medicine, ancient, 114
Electromyography in pathologic bladder, 186
Electronmicroscopy of seminal vesicle, 354
Embolism, air, after air cystometrogram, 95
Endoscopy of renal pelvis, 13
Enuresis
posterior valvular disease in, 145
studies of, 162
Epididymis
coccidioidomycosis of, 311
tuberculosis of, 329
Extravasation from bladder carcinoma, 336

FANFT for induction of bladder cancer, 63
Federal health initiatives, 608
Fibrosis and abscess, retroperitoneal, 92
Film reviews
Bifid Ureter: Modern Concepts in Diagnosis and Surgical Treatment (Amar), 364
Excretory Urography: Swick to Drip Infusion Pyelography (Evans and Sugarman), 363
Human Organ Transplantation: Part II (revisited) (Baylor University), 364
Physiology of Micturition: Part I (Scott and Bradley), 363
Simple Effective Cystourethropexy for Urinary Stress Incontinence (Greco), 364
Surgery for Penile Carcinoma (Hardner and Albert), 496
Suspension of the Female Urethra Using Tissue Adhesive (Kelami), 496
Technique of Radical Cystectomy (Skinner), 363
Transurethral Resection of the Prostate Using the Iglesias Resectoscope with Simulataneous Suction (Iglesias and Seebode), 363
Vascular and Tubular Organization of the Kidney (Beeuwkes, Bonventre, Miller, and Barger), 496
Vasectomy (Edson), 364
Ultra Short-Acting Intravenous Barbiturate Amnesia for Urological Instrumentation (Bodner), 496
Fistula
arteriovenous, 598
traumatic, 715
ureterocolic, in Hodgkin's disease, 450
ureteroperitoneal, and urinary ascites, 209
ureterovaginal, 585, 677
urethrocutaneous, 311
vesicovaginal, repair of, 109
Fowler's solution for intraurethral condyloma, 121

Gartner's duct cyst and renal agenesis, 720
Genital injuries, 596
Genitalia, duplication of, in men, 688
Genitourinary anomalies, 322
Gleet, treatment of, 367-BB
Globulin, parenteral, human, in urinary infections, 105
Granuloma, scrotal, 761
Granulomatous disease and renal involvement, 193

Hamartoma, renal, 235
Hawes orchitis compressor, 207-G
Heart failure, congestive, 598
Hematoma, subcapsular, of kidney, 519
Hernia, parastomal, 603
Hidradenitis suppurativa of scrotum and perineum, 463
Hodgkin's disease, ureterocolic fistula in, 450
Hormone therapy in hypernephroma, 669
Horseshoe kidney, 713
and renal dysplasia, 443
rupture of, 446
Hryntschak technique, modified, 550
Hydroureteronephrosis and uterine prolapse, 73
Hyperkinesia, urethral sphincter, 577
Hypernephroma, metastatic, 669
Hyperplasia or carcinoma of prostate, 758
Hypertension
with reflux, 397
renal, 140
renovascular, 241
Hypospadias
and cutaneous chordee, 293
injection technique in, 473
repair, surgical dressing for, 739

ICRF-159 in testicular tumor, 297
Ileal conduit, 402, 674
complication of, 603
Ileitis, regional, and neurogenic bladder, 593

Ileocystoplasty, 135
Immunity, cellular, 100
Immunobiology
of induced testis tumor, 97
in reproduction, 367
Immunostaging in patients with cancer, 770
Impotence, erectile, 681
Incontinence
active and passive, 693
urinary, correction with ischiocavernous collaring, 348
in girls, 162
Infection
anaerobic, 601
urinary, human globulin in, 105
Innervation, sympathetic, of bladder, 27
Intraurethral condyloma, Fowler's solution for, 121
Ischemia and ureteropelvic obstruction, 439
Isotope scintiscan, dual, 267

Kidney
arteriovenous malformation of, 706
cadaver, thrombosis of, 709
cystic disease of, 635
disease, polycystic, 623
function, differential, 665
horseshoe, 713
rupture of, 446
ipsilateral, agenesis of, 322
pelvic, on urograph and renal scan, 212
polycystic, 5
scan in pediatric urology, 665
sigmoid, adenocarcinoma, 713
subcapsular hematoma of, 519
surgical approaches to, 476
in neoplasm of, 223
transplant, marker fixation on, 607
ureteric obstruction in, 384

Letters to editor, 121, 228, 494, 623
Levodopa to relieve bone pain, 107
Lithontripteur à archet, 496-A
Lymphatic complications in renal transplantation, 650

Malformation, arteriovenous, of kidney, 706
Medical school grading policies, 748
Medic-Ana, 72-E, 173, 207-G, 235-J, 350-C, 367-BB, 496-A, 628
Medroxyprogesterone in hypernephroma, 669
Melanosis, prostatic, 617
Metastasis, pelvic, from prostatic carcinoma, 90
Methylprednisolone acetate in vasectomy, 732
Monocyte function in urinary carcinoma, 129

Nalidixic acid and pseudotumor cerebri, 204
Neoplasms
in bladder diverticula, 411
of kidney, 223
ureteral, 492
Nephrectomy, bilateral, in renal failure, 378
Nephroblastoma, extraction of, 338
Nephrology, research needs in, 624
Nephroscope and Water-Pik, 605
Nephroscopy, intraoperative, 13
Neurourologic examination, 767
Neurourology, new section on, 770
Nitrofurans, sperm-immobilizing agents, 307

Obstruction, ureteric, after ureteral reimplantation, 540
6-OHDA, 27

Page kidney, 519
Paradidymis, torsion of, 726
Paraffinoma, scrotal, 761
Penis
bifid, 688
cancer of, 571
duplication of, 688, 722
erection of, with injection technique, 473
squamous cell carcinoma of, 69
Perineum, hidradenitis suppurative of, 463
Peristalsis, ureteral, negative, 257
Peterson's rectal colpeurynter, 628
Photoendoscopy in enuresis, 145
Polyp
bilharzial ureteral, 85
xanthomatous ureteral, 214
Priapism, shunt surgery for, 1
Prolactin in prostatic hypertrophy, 557
Prolapse, uterine, and obstructive uropathy, 73
Prostate
cancer of, 107, 354, 485
with paraplegia and paraparesis, 431
coccidioidomycosis of, 311
cryosurgery in cancer of, 220, 499
5-fluorouracil in carcinoma of, 286
giant calculi of, 319
gland, infection stones in, 560
hyperplasia or carcinoma of, 758
hypertrophic, candicidin in, 80, 494
prolactin in, 557
melanosis of, 617
metastatic carcinoma of, 90
secretion of, and urethral flow, 467
stage D carcinoma of, 283
Prostatectomy, suprapubic, 550
Pseudometastasis to liver in renal carcinoma, 764
Pseudotumor cerebri and nalidizic acid, 204
^{32}P-Thio-tepa absorption in rat bladder, 33
Pyeloplasty, unsplinted, unstented, 228
Pyeloureteroplasty, medical flap, 350

Radiation therapy, complication of, 585
Radiography
abdominal, and urinary lesions, 274
in enuresis, 145
Receptors, adrenergic, 18

Reflux
ureteral reimplantation for, 540
vesicoureteral, 357, 623
Renal
adenocarcinoma, 334
agenesis and Gartner's duct cyst, 720
artery repair, extracorporeal, 532
stenosis, 140
stretching, 241
biopsy, open, 182
calculi, localization of, 13
carcinoma, 129, 514
pseudometastasis to liver in, 764
cystic disease, congenital, 635
duplication and dysplasia, 660
dysplasia and horseshoe kidney, 443
failure, nephrectomy and splenectomy in, 378
hamartoma, 235
hypertension, 140, 519
injuries due to blunt trauma, 509
involvement and granulomatous disease, 193
papillary necrosis, 352
pedicle, transperitoneal approach to, 223
pelvis, carcinoma of, 392
tumor of, 488
perfusion, normothermic ex vivo, 734
pseudotumor, 389
salvage with autotransplantation, 703
scarring and reflux, 397
surgery, new bench for, 731
protective incisions in, 476
transplantation, 643, 650, 656
and bacteremia, 198
calyceal compression in, 244
complications of, 525
role of splenectomy in, 378
ureteric obstruction in, 384
Reproduction, immunobiology in, 367

Sarcoma, reticulum cell, and ureteral obstruction, 456
Schweig's dilator, 173
Scrotum
aspiration of, 686
granuloma of, 761
hidradenitis suppurativa of, 463
Seminoma of testis, torsion of, 590
Shunt
cavernospongiosum, 1
saphenous vein, 1
Sperm immobilization with nitrofurans, 307
Sphincterometry
bedside, 57
external, complication of, 681
Spinal cord injury, sphincterometry in, 57
Splenectomy in renal failure, 378
Stones, infection, of prostate gland, 560
Strephotome, 72-A
Sympathectomy, chemical, of bladder, 27

T rosette assay and cellular immunity, 100
Testis(es)
changes postvasectomy, 190
germ cell tumors of, 567
induced tumor of, 97
interstitial cell tumor of, 459
nondescent, versus agenesis, 717
torsion of, 686
of seminoma, 590
tuberculosis of, 329
Thrombosis of cadaver kidney, 709
Thumb urethroplasty, 302
Torsion
of paradidymis, 726
of testicle, 686
Transplantation
renal, 607
and bacteremia, 198
complications of, 525
ureteral rejection during, 37
Trauma
blunt, and renal injuries, 509
to horseshoe kidney, 446
Tuberculosis of epididymis and testicle, 329
Tumor(s)
adenomatoid, of male genital tract, 325
immunology, 100
induced, of testis, 97
interstitial cell, of testis, 459
remission on 5-fluorouracil therapy, 286
of sigmoid colon after ureterosigmoidostomy, 121
superficial, of bladder, 414
testicular, 325
ICRF-159 in, 297
of testis, bilateral germ cell, 567
ureteral, management of, 44

Ultrasound diagnosis in kidney disease, 5
Ureter
bilateral carcinoma of, 217
bilharzial polypi of, 85
carcinoma of, 392
Ureteral
atresia, 443
calculi and creatine phosphokinase, 254
carcinoma, primary, 40
complication in kidney transplant, 384
injury, 677
following laparoscopic sterilization, 341
neoplasm, 492
obstruction and reticulum cell sarcoma, 456
after ureterosigmoidostomy, 448
peristalsis, negative, 257
polyp, xanthomatous, 214
reimplantation for reflux, 540
rejection during transplantation, 37
tumor, management of, 44
Ureteritis cystica, bilharzial, 261
Ureteroileal
anastomosis, 402
junction, 674

Ureteroneocystostomy, complication of, 728
Ureteropelvic obstruction, 439
Ureteroperitoneal fistula and urinary ascites, 209
Ureterovaginal fistula, 677
  bilateral, 585
Ureterosigmoidostomy
  and tumors of sigmoid colon, 121
  ureteral obstruction after, 448
Urethra
  conduit and regional compliance of, 155
  distal, exposure of, 225
  duplicated, 315
Urethral
  compliance restriction, 155
  flow and prostatic secretion, 467
  obstruction, 577
  stricture and catheter dilatation, 504
Urethroplasty, thumb, 302
Urethrotomy, internal, in girls, 162
Urinary
  anomalies and absent vas deferens, 201
  candidiasis, 494
  disease, screening of children for, 271
  infection, recurrent, 315
  lesions and abdominal radiography, 274
  phosphokinase activity, significance of, 174
  sphincteric mechanism, 421
  tract anomalies, 443
    carcinoma of, 174
    infection, human globulin in, 105
Urine, residual, in bladder, 737
Urography, intravenous, pioneer in, 613
Urolithiasis, pediatric, 51
Urology
  Egyptian contribution to, 114
  negative pressure suction in, 574
  pediatric, kidney scan in, 665
  research needs in, 624
Uropathology, diagnosis in, 485
Uropathy, obstructive, and uterine prolapse, 73
Uroradiography: case profiles, 226, 352, 622, 763
  media in, 750
Uroradiologic evaluation in children, 123

Van Buren sound, modification of, 346
Vas deferens
  anomalies, 201
  palpation of, 495
Vasectomy
  effect of on guinea pig testes, 190
  methylprednisolone acetate in, 732
  surgical technique in, 475
Vesical rupture, 426
Vesicoureteral reflux, 397, 421
  grading of, 357
  and renal pseudotumor, 389
Vesicourethral suspension, 225
Vincristine-bleomycin therapy in penile cancer, 69
Viscus perforation, 728
Volkmann, Johannes, 613

Wound
  drainage in urology, 574
  infections in renal transplantation, 656

Xanthoma and fibroepithelial polyp, 214

UROLOGY

EDITOR

Pablo Morales, M.D.
New York, New York

MANAGING EDITOR

Mary T. Politano
New York, New York

CONSULTING EDITORS

Saul Boyarsky, M.D., St. Louis, Missouri; C. Eugene Carlton, M.D., Houston, Texas; Fletcher Derrick, Jr., M.D., Charleston, South Carolina; Elwin Fraley, M.D., Minneapolis, Minnesota; Jay Y. Gillenwater, M.D., Charlottesville, Virginia; Ruben Gittes, M.D., San Diego, California; Lowell R. King, M.D., Chicago, Illinois; Gerald Murphy, M.D., Buffalo, New York; Emil A. Tanagho, M.D., San Francisco, California; Myron Tannenbaum, M.D., New York, New York; Norman R. Zinner, M.D., Los Angeles, California

ASSOCIATE EDITORS

Herbert Brendler, M.D., New York, New York; Neal S. Bricker, M.D., Bronx, New York; Joseph E. Davis, M.D., New York, New York; Norman Deane, M.D., New York, New York; Eli A. Friedman, M.D., Brooklyn, New York; Harry Grabstald, M.D., New York, New York; Russell Lavengood, Jr., M.D., New York, New York; Joseph Seebode, M.D., Newark, New Jersey; R. Keith Waterhouse, M.D., Brooklyn, New York; Ralph J. Veenema, M.D., New York, New York

FEATURE EDITORS

Manuel A. Madayag, M.D., Robert Rowan, M.D., Martin Spatz, M.D., Arthur Tessler, M.D., Adrian W. Zorgniotti, M.D., New York, New York

Volume IV, July to December, 1974

Copyright 1974

Professional Medical Services Company
55 North Maple Avenue
Ridgewood, New Jersey 07451
Printed in U.S.A.

Contents of Volume IV

JULY 1974

Shunt Surgery for Priapism: Review of Results 1
MALCOLM D. COSGROVE, M.D., AND MICHAEL A. LAROCQUE, M.D.

Polycystic Kidney Disease: Earlier Diagnosis Using Ultrasound 5
EDWARD G. LUFKIN, M.D., ALLEN C. ALFREY, M.D.,
MARK E. TRUCKSESS, M.D., AND JOSEPH H. HOLMES, M.D.

Intraoperative Nephroscopy 13
ELMAR HERTEL, M.D.

Effect of Sympathomimetic Drugs on Canine Bladder: Surgical Model for Assessment of Regional Differences 18
JOHN W. DOWNIE, PH.D., SAID A. AWAD, M.B., B.CH., F.R.C.S. (C),
DENIS W. LYWOOD, B.SC., ANDREW W. BRUCE, M.B., B.CH., F.R.C.S. (C)

Sympathetic Innervation and Chemical Sympathectomy of Canine Bladder 27
ALAN J. WEIN, M.D., JOHN G. GREGORY, M.D., WILLIAM J. CROMIE, M.D.,
JOSEPH N. CORRIERE, JR., M.D., AND DAVID M. JACOBOWITZ, PH.D.

^{32}P-Labeled Thio-Tepa Absorption in Normal Rat Bladders: Potential Guide for Intravesical Chemotherapy in Bladder Cancer 33
P. J. PUCHNER, M.D., R. J. VEENEMA, M.D., P. TOMASHEFSKY, M.D.,
T. PINZUS, AND M. TANNENBAUM, M.D.

Ureteral Rejection in Isolated Allograft Ureter 37
JOHN H. TEXTER, JR., M.D., GARY BOKINSKY, M.D., AND
BRUCE BROECKER, M.D.

Primary Ureteral Carcinoma 40
ROBERT BURGER, M.D., AND HARLAN J. SPJUT, M.D.

Conservative Management of Ureteral Tumor 44
WILLAM C. DEWOLF, M.D., RICHARD RODGERS, M.D., AND
CLYDE BLACKARD, M.D.

Urolithiasis in Children 51
ROBERT M. FARRELL, M.D., AND VICTOR F. MARSHALL, M.D.

Bedside Sphincterometry 57
HARRY W. HERR, M.D., IGAL SILBER, M.D., AND
DONALD C. MARTIN, M.D.

Diabetes-Related Need for Circumcision 60
MYRON I. MURDOCK, M.D., AND STUART M. SELIKOWITZ, M.D.

Chemotherapy of Experimental Transitional-Cell Carcinoma 63
JEAN B. DEKERNION, M.D., MARK S. SOLOWAY, M.D., AND LESTER PERSKY, M.D.

Chemotherapy for Metastatic Squamous-Cell Carcinoma of Penis: Combination of Vincristine and Bleomycin 69
RICHARD D. WILLIAMS, M.D., AND CLYDE E. BLACKARD, M.D.

Obstructive Uropathy Associated with Uterine Prolapse 73
LEONARD J. RUDIN, M.D., MAGUID R. MEGALLI, M.D., AND JOHN K. LATTIMER, M.D.

Efficacy of Candicidin in Benign Prostatic Hypertrophy 80
LAZARUS A. ORKIN, M.D.

Bilharzial (Schistosomal) Polypi of Ureter 85
SAAD MOHAMED SAAD, M.B., M.CH., AND HANAFY MOHAMED HANAFY, M.D.

Metastatic Carcinoma of Prostate 90
DAVID A. PARKER, M.D., PAUL WAINSCOTT, M.D., AND WILLIAM RENERT, M.D.

Retroperitoneal Fibrosis Associated with Retroperitoneal Abscess 92
JOHN R. WHITTAKER, M.D., SELWYN Z. FREED, M.D., AND SYED A. HALEEM, M.D.

Fatal Air Embolism Following Air Cystometrogram 95
JACK L. SUMMERS, M.D., MANLEY L. FORD, M.D.,
WALTER A. KEITZER, M.D., AND JAMES E. WILKERSON, M.D.

Immunobiology of Induced Testis Tumor 97
N. JAVADPOUR, M.D.

T Rosette Assay: In Vitro Correlate of Cellular Immunity 100
WILLIAM J. CATALONA, M.D., CLAUDE POTVIN, M.D., F.R.C.S. (C), JOHN TARPLEY, M.D., AND PAUL B. CHRETIEN, M.D.

Use of Parenteral Human Globulin in Acute, Chronic, and Recurrent Urinary Tract Infections 105
JOHN A. ARCADI, M.D.

Cancer of Prostate: Relief of Bone Pain with Levodopa 107
N. SADOUGHI, M.D., M. RAZVI, M.D., I. BUSH, M.D., R. ABLIN, PH.D., AND P. GUINAN, M.D.

Rotation of Bladder Flap for Repair of Vesicovaginal Fistula 109
J. EDSON PONTES, M.D.

Vesical Stabilization: Useful Adjunct in Radical Retropubic Prostatectomy 112
D. L. MCCULLOUGH, M.D., AND A. P. MCLAUGHLIN, III, M.D.

Ancient Egyptian Medicine: Contribution to Urology 114
HANAFY MOHAMED HANAFY, M.D., SAAD MOHAMED SAAD, M.B., M.CH., AND MOHAMED MAHMOUD AL-GHORAB, M.B., M.CH.

AUGUST 1974

Uroradiologic Evaluation in Pediatric Patients: Guidelines 123
CHARLES E. SHOPFNER, M.D.

Defective Monocyte Chemotactic Response in Genitourinary Carcinoma 129
STANLEY BROSMAN, M.D., and MARVIN S. HAUSMAN, M.D.

Ileocystoplasty 135
YVES L. HOMSY, M.D., F.R.C.S. (C), and EVERETT C. REID, M.D., F.R.C.S. (C)

The Renal Hypertensive Suspect with Coexistent Lesions 140
LEONARD S. MARKS, M.D., ROBERT B. SMITH, M.D., and JOSEPH J. KAUFMAN, M.D.

Radiographic and Photoendoscopic Studies in Posterior Urethral Valves in Enuretic Boys 145
SAMUEL J. ARNOLD, M.D., and ARTHUR GINSBURG, M.D.

Conduit and Regional Compliance of Female Canine Urethra: Observations During Voiding and Passive Urethral Infusion 155
SUBBARAO V. YALLA, M.D., and HARRY M. BURROS, M.D.

Studies of Enuresis: VII. Results of Distal Internal Urethrotomy in Girls with Juvenile Urinary Incontinence 162
DAVID T. MAHONY, M.D., and ROLAND O. LAFERTE, M.D.

Carcinoma of Urinary Tract: Clinical Significance of Urinary Phosphokinase Activity in Diagnosis 174
NORMAN L. BLOCK, M.D., JOSEPH JAKSY, M.D., and ARTHUR N. TESSLER, M.D.

Open Renal Biopsy: New Technique 182
FRANCIS F. BARTONE, M.D., and HONG KIM, M.D.

Electromyography in Pathologic Bladder 186
WINSTON JONES, M.D., WILLIAM J. LAJOIE, M.D., and MALCOM D. COSGROVE, M.D.

Effect of Vasectomy on Guinea Pig Testes 190
RICHARD G. SALERNO, M.D., PETER S. ALBERT, M.D., and JOSEPH E. DAVIS, M.D.

Chronic Granulomatous Disease of Childhood with Renal Involvement 193
STEPHEN D. BLOOMBERG, M.D., RICHARD M. EHRLICH, M.D., HAROLD C. NEU, M.D., and WILLIAM A. BLANC, M.D.

Shigella Sonnei Bacteremia: Unusual Antibody Response from Immunosuppressive Therapy Following Renal Transplantation 198
E. NETER, M.D., C. MERRIN, M.D., M. J. SURGALLA, PH.D., and Z. WAJSMAN, M.D.

Congenital Absence of Vas Deferens with Ipsilateral Urinary Anomalies 201
C. B. EMERY, M.D., A. M. B. GOLDSTEIN, M.D., and J. W. MORROW, M.D.

Pseudotumor Cerebri Associated with Nalidixic Acid 204
K. GOPINATHA RAO, M.S., F.R.C.S.

Urinary Ascites Secondary to Ureteroperitoneal Fistula 209
G. V. BOURDEAU, M.D., S. J. JINDAL, F.R.C.P. (C), R. R. GILLIES, F.R.C.P. (C), and J. V. BERRY, F.R.C.S. (C)

Pelvic Kidney Secondary to False-Positive Renal Scan: Error in Diagnosis 212
MAHENDRA S. SHAH, M.D., JOEL C. ULLMAN, M.D., and JOSEPH KARP, M.D.

Xanthomatous Ureteral Polyp 214
EDWARD C. ELSON, M.D., and A. P. MCLAUGHLIN, III, M.D.

Simultaneous Bilateral Carcinoma of Ureter 217
IBRAHIM T. SÖZER, M.D.

Closed Perineal Cryosurgery in Prostatic Cancer: New Probe and Technique 220
MAGUID R. MEGALLI, M.D., EROL O. GURSEL, M.D., and RALPH J. VEENEMA, M.D.

Transperitoneal Approach to Renal Pedicle 223
RUSSELL SCOTT, JR., M.D.

Effective Aid for Vesicourethral Suspension 225
SUMNER MARSHALL, M.D.

Case Profile: Arthur N. Tessler, M.D. 226

SEPTEMBER 1974

Renal Hamartoma: Current Concepts of Diagnosis and Surgical Management 235
D. L. MCCULLOUGH, M.D.

Renal Artery Stretching and Renovascular Hypertension: An Experimental Study 241
PETER H. PETRITSCH, M.D., STEPHEN A. SACKS, M.D., AND JOSEPH J. KAUFMAN, M.D.

Calyceal Compression in Renal Transplantation: Its Value in Assessment of Rejection 244
DANIEL S. MITCHELL, M.D., ROBERT C. STADALNIK, M.D., AND MICHAEL J. SULLIVAN, M.D.

Adrenal Cysts: Diagnosis and Management 248
JAMES M. WILSON, M.D., DAVID M. WOODHEAD, M.D., AND ROBERT B. SMITH, M.D.

Elevated Creatine Phosphokinase in Patients with Ureteral Calculi: Cause for Unwarranted Concern of Coronary Occlusion 254
HOWARD C. HALVORSON, M.D., HERBERT I. BIAS, M.D., PAUL E. KALDAHL, M.D., AND DONALD D. ALBERS, M.D.

Negative Peristaltic Complexes Recorded from Ureter 257
R. KADIVAR, M.D., AND M. TABATABAI, M.D.

Bilharzial (Schistosomal) Ureteritis Cystica 261
SAAD MOHAMED SAAD, M.B., M.CH., AND HANAFY MOHAMED HANAFY, M.D.

Dual Isotope Scintiscan: New Method for Evaluating Bladder Function 267
LARRY I. LIPSHULTZ, M.D., AND JOSEPH N. CORRIERE, JR., M.D.

Screening of School Children for Urinary Disease 271
WALTER A. KEITZER, M.D., JAMES S. ALLEN, M.D., AND JACK L. SUMMERS, M.D.

Radiologic and Postmortem Survey of Abdominal Lesions: With Special Reference to Lesions of Urinary Tract 274
IAIN MCKAY., M.B., F.R.C.S., JOHN SINCLAIR, M.B., F.R.C.S., ROY SCOTT, M.B., F.R.C.S., AND J. G. DUNCAN, M.B., F.R.C.S., M.R.C.P.

Rectal Bladder with Perineal Colostomy for Urinary Diversion 278
M. A. GHONEIM, M.CH., AND I. SHOUKRY, M.CH.

Stage D Prostatic Carcinoma: Survival Rate in Relapsed Patients Following New Forms of Palliation 283
K. WELVAART, M.D., C. E. MERRIN, M.D., A. MITTELMAN, M.D., AND G. P. MURPHY, M.D., D.SC.

Host-Tumor Interactions During 5-Fluorouracil Therapy for Prostatic Carcinoma 287
WILLIAM J. CATALONA, M.D.

Cutaneous Chordee: Fact or Fancy 293
JOHN N. WETTLAUFER, M.D.

ICRF-159 in Treatment of Germinal Testicular Tumor in Animals 297
BALFOUR M. MOUNT, F.R.C.S. (C), AND MIRIAM HUSK, B.SC.

"Thumb" Urethroplasty: A Modification and Comparative Study 302
STEPHEN V. KISHEV, M.D.

Nitrofurans: Sperm-Immobilizing Agents: Their Tissue Toxicity and Clinical Application 307
PETER S. ALBERT, M.D., DAVID T. MININBERG, M.D., AND JOSEPH E. DAVIS, M.D.

Coccidioidomycosis of Prostate and Epididymis: With Urethrocutaneous Fistula 311
JAMES E. GOTTESMAN, M.D.

Recurrent Urinary Tract Infection: With Persistent Wolffian Duct Masquerading as Duplicated Urethra 315
GERALD W. FRIEDLAND, M.D., AND THOMAS A. STAMEY, M.D.

Giant Prostatic Calculi 319
ATMARAM S. GAWANDE, M.D., MADHAV H. KAMAT, M.D., AND JOSEPH J. SEEBODE, M.D.

Ectopia of Seminal Vesicle: Associated with Agenesis of Ipsilateral Kidney 322
STEVE A. HOLT, M.D., AND NORMAN E. PETERSON, M.D.

Adenomatoid Tumor of Male Genital Tract 325
DEJO VIPRAKASIT, M.D., MYRON TANNENBAUM, M.D., AND ARTHUR M. SMITH, M.D.

Tuberculosis of Epididymis and Testicle Presenting as Hydrocele 329
HAROLD R. REEVE, M.D., JOHN L. WEINERTH, M.D., AND LLOYD J. PETERSON, M.D.

Primary Renal Candidiasis Masking Transitional-Cell Carcinoma 332
MAJ. JAMES S. ROBBINS, III, COL. BERNHARD T. MITTEMEYER, AND COL. ANTHONY A. BORSKI

Bladder Tumor Implant from Renal Adenocarcinoma 334
PATERNO A. REMIGIO, M.D., AND CONRADO M. RAMOS, M.D.

Spontaneous Peripelvic Extravasation Due to Bladder Carcinoma 336
MICHAEL PERGAMENT, M.D., RICARDO GONZALEZ, M.D., AND CLYDE E. BLACKARD, M.D.

Successful Extraction of Large Intracaval Isthmus of Nephroblastoma 338
JOHN F. REDMAN, M.D., GILBERT S. CAMPBELL, M.D., AND GLEN A. ROUNTREE, M.D.

Ureteral Injury: Complication of Laparoscopic Sterilization 341
JAMES N. STENGEL, D.O., EUGENE S. FELDERMAN, M.D., AND DANILO ZAMORA, M.D.

Nephrogenic Adenoma of Bladder 343
ENNO KAANY, M.D., AND STEPHAN L. WERNER, M.D.

A Sound-Catheter: Modification of Van Buren Sound 346
LOUIS W. DOROSHOW, M.D.

Male Urinary Incontinence: Correction with Ischiocavernous Muscles Collaring Method 348
FUSEN H. CHEN, M.D.

Dismembered Medial Flap Pyeloureteroplasty 350
MILTON E. GORDON, M.D.

Case Profile of the Month 352
ARTHUR N. TESSLER, M.D.

Differential Diagnosis in Uropathology: I. Carcinoma of Prostate Versus Seminal Vesicle 354
MYRON TANNENBAUM, M.D.

A Plea for Grading Vesicoureteric Reflux 357
ARNOLD H. COLODNY, M.D., AND ROBERT L. LEBOWITZ, M.D.
New Section on Uropathology 358

OCTOBER 1974

Immunobiology of Reproductive Processes in Men: Current Concepts 367
JAMES S. COCHRAN, M.D.
Bilateral Nephrectomy and Splenectomy in Renal Failure 378
T. E. TALLEY, M.D., C. L. LINKE, M.D., C. A. LINKE, M.D.,
A. G. MAY, M.D., C. ANDRUS, M.D., M. F. BRYSON, M.D.,
A. T. K. COCKETT, M.D., I. N. FRANK, M.D., R. B. FREEMAN, M.D.,
W. A. GREENE, M.D., R. G. MERIN, M.D., R. C. PABICO, M.D.,
R. C. UFFERMAN, M.D., AND Y. N. YAKUB, M.D.
Acute Ureteric Obstruction of Kidney Transplant:
Management of Late Complications 384
LUCA C. RATTAZZI, M.D., RICHARD L. SIMMONS, M.D.,
JOSHUA MILLER, M.D., ROBERT CASALI, M.D., AND JOHN S. NAJARIAN, M.D.
Vesicoureteral Reflux Simulating Renal Mass Lesions 389
ROBERT M. WEISS, M.D., AND MARTIN SCHIFF, JR., M.D.
Transitional-Cell Carcinoma of Renal Pelvis and Ureter:
Retrospective Review of 40 Patients 392
MIMS GAGE OCHSNER, M.D., WILLIAM BRANNAN, M.D.,
HARRY S. POND, III, M.D., AND HAROLD T. COLLINS, M.D.
Renal Scarring and Primary Reflux in Adults 397
EUGENE V. CATTOLICA, M.D.
Muscular Nipple Ureteroileal Anastomosis to Prevent Reflux 402
P. R. REGE, M.D., I. K. MALIK, M.D., R. G. WENDEL, M.D., AND
A. T. EVANS, M.D.
Verrucose Squamous Carcinoma of Bladder 407
I. EL SEBAI, M.D., M. SHERIF, M.D., M. N. EL BOLKAINY, M.D.,
M. A. MANSOUR, M.D., AND M. A. GHONEIM, M.D.
Neoplasms in Bladder Diverticula 411
WARREN H. SIEGEL, M.D.
Superficial Bladder Tumor: Aspects of Clinical Progression 414
M. J. VARKARAKIS, M.D., J. GAETA, M.D., R. H. MOORE, M.S.,
AND G. P. MURPHY, M.D., D.SC.
Reduced Bladder Capacity: Cause for Vesicoureteral Reflux 421
UDO JONAS, M.D., AND EMIL A. TANAGHO, M.D.
Conservative Management of Vesical Rupture 426
A. P. MULKEY, JR., M.D., AND ROY WITHERINGTON, M.D.
Paraplegia and Paraparesis Due to Prostatic Cancer:
Use of Intravenous Diethylstilbestrol Diphosphate 431
CHARLES E. HAWTREY, M.D., MELTON J. WELCH, JR., M.D.,
JOSEPH D. SCHMIDT, M.D., DAVID A. CULP, M.D., AND RUBIN H. FLOCKS, M.D.
Prostatic Acid Phosphatase Levels: Significance in Serum and Bone Marrow 435
SUMNER MARSHALL, M.D., RICHARD P. LYON, M.D., AND
MALCOLM P. SCOTT, JR., M.D.
Obstruction of Ischemic Ureteropelvic Junction 439
GERALD W. FRIEDLAND, M.D., MICHAEL J. DROLLER, M.D., AND
THOMAS A. STAMEY, M.D.
Horseshoe Kidney with Unilateral Renal Dysplasia 443
ALBERT P. CORICA, M.D., AND HAROLD E. MARDEN, JR., M.D.
Rupture of Horseshoe Kidney in a Child: Secondary to Blunt Abdominal Trauma 446
LT. COL. CLYDE M. GAFFNEY, USAF (MC)
Transient Ureteral Obstruction by Bacillary Dysentery after
Ureterosigmoidostomy 448
AUSTIN L. SPITZER, M.D., AND DEREK P. STABLES, D.M.R.D.

Ureterocolic Fistula: Associated with Hodgkin's Disease 450
R. SANKARAN, M.D., A. E. CHESLEY, M.D., AND M. C. KHADILKAR, M.D.
Adenocarcinoma of Tongue Metastatic to Bladder 454
ROMAN A. CHALBAUD, M.D., AND DOUGLAS E. JOHNSON, M.D.
Reticulum Cell Sarcoma: Unusual Cause of Ureteral Obstruction 456
ISAAC KOZIOL, M.D.
Interstitial Cell Tumor of Testis in Adult 459
WINSTON G. JONES, M.D., RICHARD ONOFRIO, M.D., AND
ABRAHAM M. B. GOLDSTEIN, M.D.
Hidradenitis Suppurativa of Scrotum and Perineum 463
JOSEPH N. WARD, M.D., HIROSHI WASHIO, M.D., AND HARRY S. DAVID, M.D.
Prostatic Secretion and Urethral Flow 467
SAMUEL J. ARNOLD, M.D., ARTHUR BABSON, PH.D., AND
ARTHUR GINSBURG, M.D.
Injection Technique to Induce Penile Erection 473
R. F. GITTES, M.D., AND A. P. MCLAUGHLIN, III, M.D.
Immobilization of the Vas in Office Vasectomy 475
JAMES A. ROBERTS, M.D.
Muscle Protective Incisions in Renal Surgery 476
HECTOR BENSIMON, M.D.
Education and Recertification 481
JAMES F. GLENN, M.D.
Differential Diagnosis in Uropathology. II. Urologic Artifact and/or Pathologist's Dilemma 485
MYRON TANNENBAUM, M.D.
Mucus-Producing Adenocarcinoma of Renal Pelvis 488
JUAN AGUILO, M.D., AND WILLIAM L. FURLOW, M.D.
Case Profile of the Month 492
KENNETH LICKER, M.D.

NOVEMBER 1974

Cryosurgery for Prostatic Carcinoma 499
LAWRENCE W. JONES, M.D.
Urethral Stricture Treated with Soft Catheter Dilatation: Reappraisal of an Old Technique 504
SIVAPRASAD MADDURI, M.D., MADHAV H. KAMAT, M.D., AND
JOSEPH J. SEEBODE, M.D.
Renal Injuries Caused by External Blunt Trauma: Moderate Approach to Serious Injuries 509
MORTON BOGASH, M.D., HOWARD POLLACK, M.D., AND JERRY L. CATES, M.D.
Management of Intrarenal Peripelvic Cysts 514
KARL-ERIC JOHANSON, M.D., LEONARD PLAINE, M.D.,
EDUARDO FARCON, M.D., AND PABLO MORALES, M.D.
Liquefied Subcapsular Hematomas of Kidney 519
RALPH A. DOWNS, M.D.
Urologic Complications of Renal Transplantation 525
CHARLES M. LYNNE, M.D., HERMAN M. CARRION, M.D., AND
BEN A. VANDERWERF, M.D.
Extracorporeal Renal Artery Repair and Autotransplantation 532
RUSSELL K. LAWSON, M.D., AND CLARENCE V. HODGES, M.D.
Later Ureteric Obstruction Following Ureteral Reimplantation for Reflux: A Warning 540
ROY A. FILLY, M.D., GERALD W. FRIEDLAND, M.D.,
WILLIAM R. FAIR, M.D., AND DUNCAN E. GOVAN, M.D.
Large-Capacity Bladder: A Urodynamic Survey 544
J. WEIR, M.B.B.S., M.R.C.P., D.M.R.D., AND P. F. JAQUES, M.B.B.S., D.M.R.D.

Suprapubic Prostatectomy: Modified Hryntschak Technique 550
ROY WITHERINGTON, M.D., AND W. C. SHELOR, JR., M.D.

Role of Prolactin in Benign Prostatic Hypertrophy 557
JOHN D. BIRKHOFF, M.D., JOHN K. LATTIMER, M.D., AND ANDREW G. FRANTZ, M.D.

Infection Stones of Prostate Gland: Laboratory Diagnosis and Clinical Management 560
EDWIN M. MEARES, JR., M.D.

Bilateral Sequential Germ Cell Tumors of Testis 567
DOUGLAS E. JOHNSON, M.D., AND JAMES E. MORNEAU, M.D.

Radiation Therapy of Penile Cancer 571
CHARLES D. KELLEY, M.D., KEITH ARTHUR, M.D., EDWARD ROGOFF, M.D., AND HARRY GRABSTALD, M.D.

Use of Negative Pressure Suction in Urology 574
ROBERT P. NELSON, M.D., AND DANIEL C. MERRILL, M.D.

Primary External Urethral Sphincter Hyperkinesia in a Boy 577
S. GRANT MULHOLLAND, M.D., SUBBARAO V. YALLA, M.D., DAVID M. RAEZER, M.D., AND JOHN W. DUCKETT, JR., M.D.

Nephrogenic Diabetes Insipidus: Associated with Posterior Urethral Valves 581
NEIL H. BAUM, M.D., ROBERT BURGER, M.D., AND C. EUGENE CARLTON, JR., M.D.

Acupuncture Needle in Bladder 584
JOHNNY B. ROY, M.D.

Bilateral Ureterovaginal Fistula: Complication of Radiation Therapy 585
JEFFREY M. IGNATOFF, M.D., AND JOHN B. GRAHAM, M.D.

Torsion of Intra-Abdominal Seminoma of Testis 590
DOUGLAS S. DAHL, M.D.

Transient Neurogenic Bladder Secondary to Presacral Abscess: Association with Regional Ileitis 593
STEPHEN M. RUDY, M.D., AND EMIL A. TANAGHO, M.D.

High Bilateral Funiculo-Orchiectomy: Secondary to Avulsion Injury 596
THOMAS B. MCGINNIS, M.D., JOHN F. REDMAN, M.D., AND NABIL K. BISSADA, M.D.

Intractable Congestive Heart Failure: Following Brachiocephalic Interposition Saphenous Vein Arteriovenous Fistula 598
SUVAS G. DESAI, M.D., AND CALVIN B. ERNST, M.D.

Clostridial Cystitis Emphysematosa 601
JON S. WAYLAND, M.D., AND MARK D. KIVIAT, M.D.

Parastomal Hernia Causing Anuria: Unusual Complication of Ileal Conduit Diversion 603
CHARLES M. LYNNE, M.D., VICTOR A. POLITANO, M.D., AND RONALD L. COHEN, M.D.

Use of Water-Pik and Nephroscope 605
ROBERT P. GIBBONS, M.D., ROY J. CORREA, JR., M.D., KENNETH B. CUMMINGS, M.D., AND J. TATE MASON, M.D.

Metal Marker Fixation on Transplanted Kidneys 607
CHARLES B. ANDERSON, M.D.

Federal Health Initiatives 608
JAMES W. SYMINGTON

Johannes Volkmann, M.D.: Pioneer in Intravenous Urography 613
PETER RATHERT, M.D., HANSJÖRG MELCHIOR, M.D., AND WOLFGANG LUTZEYER, M.D.

Differential Diagnosis in Uropathology: III. Melanotic Lesions of Prostate: Blue Nevus and Prostatic Epithelial Melanosis 617
MYRON TANNENBAUM, M.D.

Case Profile of the Month 622
JORDAN BROWN, M.D.

DECEMBER 1974

Congenital Cystic Disease of Kidney: Classification and Manifestations 635
A. RICHARD KENDALL, M.D., HOWARD M. POLLACK, M.D., AND LESTER KARAFIN, M.D.

Renal Transplantation:
I. Use of Donor Organs with Multiple Vessels 643
L. H. BANOWSKY, M.D., D. F. SIEGAL, M.D., C. B. HEWITT, M.D., B. H. STEWART, M.D., R. A. STRAFFON, M.D., M. O. MAGNUSSON, M.D., AND W. E. BRAUN, M.D.
II. Lymphatic Complications 650
L. H. BANOWSKY, M.D., J. FRANCIS, M.D., W. E. BRAUN, M.D., AND M. O. MAGNUSSON, M.D.
III. Prevention of Wound Infections 656
L. H. BANOWSKY, M.D., J. E. MONTIE, M.D., W. E. BRAUN, M.D., AND M. O. MAGNUSSON, M.D.

Renal Duplication and Dysplasia 660
EUGENE V. PERRIN, M.D., LESTER PERSKY, M.D., ARTHUR TUCKER, M.D., AND BLAIR CHRENKA, B.S.

Differential Kidney Scan in Pediatric Urology 665
RAPHAEL PIERETTI, M.D., DAVID GILDAY, M.D., AND ROBERT JEFFS, M.D.

Hormonal Therapy in Metastatic Hypernephroma 669
LLOYD J. PETERSON, M.D., JOHN H. GRIMES, M.D., JOHN E. DEES, M.D., AND E. EVERETT ANDERSON, M.D.

Retroperitoneal Reexploration of Ureteroileal Junction 674
JOHN F. REDMAN, M.D., LADD J. SCRIBER, M.D., AND NABIL K. BISSADA, M.D.

Nonsurgical Management of Ureterovaginal Fistula 677
D. DOUGLAS PETERSON, M.D., DONALD T. LUCEY, M.D., AND F. A. FRIED, M.D.

Erectile Impotence: Complication of External Sphincterotomy 681
LAWRENCE SCHOENFELD, M.D., HERNAN M. CARRION, M.D., AND VICTOR A. POLITANO, M.D.

Scrotal Aspiration: Aid in Early Differentiation Between Torsion of Spermatic Cord and Acute Epididymo-orchitis 686
HOWARD L. MORGENLANDER, M.D., AND GILBERT J. WISE, M.D.

Duplication of External Genitalia in Men 688
A. SOTIROPOULOS, M.D., A. USON, M.D., AND J. K. LATTIMER, M.D.

Active and Passive Incontinence: Differential Diagnosis 693
DONALD M. GLEASON, M.D., MANFRED R. BOTTACCINI, PH.D., AND ROBERT J. REILLY, M.D.

Renal Salvage Through Autotransplantation 703
R. R. PFISTER, M.D., AND B. HUSBERG, M.D.

Arteriovenous Malformations of Kidney 706
LLOYD K. MARK, M.D.

Thrombosis of Perfused Cadaver Kidney 709
FREDERICK K. MERKEL, M.D., SANDRA K. SEIM, M.S., KENT ARMBRUSTER, M.D., CASIMIR F. FIRLIT, M.D., AND LOWELL R. KING, M.D.

Adenocarcinoma in a Sigmoid Kidney 713
RICHARD B. MALKIN, M.D., AUSTIN I. DODSON, JR., M.D., AND WARREN W. KOONTZ, JR., M.D.

Intrarenal Arterial Collaterals Simulating Malignant Tumor in Traumatic Arteriovenous Fistula 715
M. KINKHABWALA, M.D., R. DZIADIW, M.D., AND U. PATIL, M.D.

Testicular Nondescent Versus Agenesis: Importance of Diagnosis and Correct Surgical Management 717
JAY J. STEIN, M.D., AND RICHARD VON BUEDINGEN, M.D.

Gartner's Duct Cyst and Ipsilateral Renal Agenesis 720
WILLIAM F. GADBOIS, M.D., AND JOHN W. DUCKETT, JR., M.D.

Duplication of Penis 722
CHARLES F. JOHNSON, M.D., C. EUGENE CARLTON, JR., M.D., AND NORBORNE B. POWELL, M.D.

Torsion of the Paradidymis 726
EUGENE V. CATTOLICA, M.D.
Viscus Perforation: Unusual Complication of Ureteroneocystostomy 728
JOEL M. KAUFMAN, M.D., EDWARD J. MCGUIRE, M.D., AND ARNOLD M. BASKIN, M.D.
New Bench for Extracorporeal Renal Surgery 731
RICHARD MILSTEN, LCDR, (MC) USNR
Use of Methylprednisolone Acetate in Vasectomy 732
FREDERICK J. FRENSILLI, M.D., MARK A. IMMERGUT, M.D., AND EDWARD C. GILBERT, M.D.
Normothermic Ex Vivo Renal Perfusion 734
E. DEAN BAIR, M.D., THOMAS A. BORDEN, M.D., AND EDWARD T. PETER, M.D.
Estimation of Residual Urine in Bladder: Use of Vesical "Thrill" Test 737
UMESH B. PATIL, M.D.
Surgical Dressing for Hypospadias Repair 739
JOHN F. REDMAN, M.D., AND JOHN P. SMITH, M.D.
Death and Dying: Attitudes in a Teaching Hospital 741
BALFOUR M. MOUNT, M.D., ALLAN JONES, B.SC., AND ANDREW PATTERSON, B.SC.
Medical School Grading Policies 748
AUSTIN S. LITVAK, M.D., AND J. WILLIAMS MCROBERTS, M.D.
Uroradiographic Media 750
MOSES SWICK, M.D.
Atypical Epithelial Hyperplasia or Carcinoma of Prostate Gland: The Surgical Pathologist at an Impasse? 758
MYRON TANNENBAUM, M.D., PH.D.
Mineral Oil Granulomatosis of Scrotum 761
LOUIS G. NEFT, M.D., AND DANIEL C. MERRILL, M.D.
Case Profile of the Month 763
MARK COHEN, M.D.
Angiographic Pseudometastasis to Liver in Renal Cell Carcinoma 764
DANA C. NIENDORF, M.D., ERVIN PHILIPPS, M.D., AND JOHN M. PALMER, M.D.
The Neurourologic Examination 767
WILLIAM E. BRADLEY, M.D., GERALD W. TIMM, M.D., AND F. BRANTLEY SCOTT, M.D.
"Immunostaging" Patients with Malignant Disease 770
PATRICK D. GUINAN, M.D., RICHARD J. ABLIN, PH.D., GAILON R. BRUNS, B.A., AND IRVING M. BUSH, M.D.
New Section on Neurourology 770

CAREER OPPORTUNITIES

As a service to you, each month, *Urology* will carry a diverse listing of career opportunities in urology and related fields. If you are looking for a position, a partner, an associate, and other, please clip and mail the request form below. No charge, of course.

All appropriate ad requests received on or before the fifth of each month will appear in the next issue then being prepared for publication. Ads reaching us after the deadline will be held for the next issue.

To reply to a "blind" ad, mark your envelope with the box number designated in the ad. We shall forward all responses promptly, to the advertisers.

Managing Editor
UROLOGY, P.O. Box 643, Ridgewood, N.J. 07451

MESSAGE: Please type or print — limit to 35 words

_____

_____

_____

_____

_____

_____

_____

From: _____
Physician's Signature

_____
Physician's Name (Type or Print)

_____
Address

_____
City State Zip

_____
Telephone Area Code

☐ Use my name.

☐ Replace my name with box number.

☐ Include my telephone number in ad.

As effective today as it was in 1938... Still keeping urine sterile.

Over the last 36 years, Mandelamine has provided one basic action. By converting to formaldehyde in acid urine, *it helps keep urine sterile.* And this provides one basic benefit—*to help prevent cystitis from recurring.* After ruling out complications, you can effectively use Mandelamine against both gram-positive and gram-negative organisms—without major organ toxicity or the development of resistance.

Mandelamine is effective for other reasons, too. It's well-tolerated for long-term use...with only an occasional skin rash or dysuria reported. It's economical...significantly less expensive tablet for tablet than any other branded methenamine salt at equivalent doses. And it's available in a variety of dosage forms that fit the needs of your patients...from pediatric to geriatric.

Mandelamine®
(methenamine mandelate)
To help prevent cystitis from recurring

Mandelamine® (methenamine mandelate)
Caution: Federal law prohibits dispensing without prescription.

Mandelamine, a urinary antibacterial agent, is the chemical combination of mandelic acid with methenamine.

Indications: Mandelamine (methenamine mandelate) is indicated for the suppression or elimination of bacteriuria associated with pyelonephritis, cystitis, and other chronic urinary tract infections; also for infected residual urine sometimes accompanying neurologic diseases. When used as recommended, Mandelamine is particularly suitable for long-term therapy because of its safety and because resistance to the nonspecific bactericidal action of formaldehyde does not develop. Pathogens resistant to other antibacterial agents may respond to Mandelamine because of the nonspecific effect of formaldehyde formed in an acid urine.

Contraindications: Contraindicated in renal insufficiency.

Precautions: Dysuria may occur (usually at higher than recommended dosage). This can be controlled by reducing the dosage and the acidification. When urine acidification is contraindicated or unattainable (as with some urea-splitting bacteria), the drug is not recommended.

Adverse Reaction: An occasional patient may experience gastrointestinal disturbance or a generalized skin rash.

Dosage and Management: The average adult dosage is 4 grams daily given as 1.0 gram after each meal and at bedtime. Children 6 to 12 should receive half the adult dose and children 5 years of age or under should receive 250 mg per 30 lb of body weight, four times daily. (See chart).

Mandelamine Dosages

Strength	Dosage Form	Dosage
1 gm	Mandelamine Tablets Mandelamine Granules (1.0 gm Packet)	Adults: 1 Tablet, q.i.d. 1 Packet, q.i.d.*
½ gm	Mandelamine Suspension Forte 500 mg/tsp	Children 6-12: 1 teaspoonful or 1 tablet, q.i.d. Adults: 2 teaspoonfuls or 2 tablets, q.i.d.
	Mandelamine ½ gm Tablets	
	Mandelamine Granules (0.5 gm Packets)	Adults: 2 Packets, q.i.d.*
¼ gm	Mandelamine Suspension 250 mg/tsp Mandelamine ¼ gm Tablets	Children 5 or under 1 teaspoonful or 1 tablet per 30 lb body weight, q.i.d.

*To be dissolved in 2-4 oz. of water immediately before using.

Since an acid urine is essential for antibacterial activity with maximum efficacy occurring at pH 5.5 or below, restriction of alkalinizing foods and medication is thus desirable. If testing of urine pH reveals the need, supplemental acidification should be given.

Supplied: 1 gm Tablets, 1.0 gm, purple enteric coated, bottles of 100 and 1000. ½ gm Tablets, 0.5 gm, brown enteric coated, bottles of 100 and 1000 tablets. ¼ gm Tablets, 0.25 gm, brown enteric coated, bottles of 100 and 1000 tablets.

Additional Dosage Forms: Mandelamine Suspension Forte containing 500 mg methenamine mandelate per teaspoonful, in bottles of 8 fl oz and 16 fl oz. This pink, cherry-flavored Suspension Forte is especially useful for pediatric patients and for those adults who cannot or will not swallow a tablet. Mandelamine Suspension—Each cream-colored coconut-flavored teaspoonful of Mandelamine Suspension contains 250 mg methenamine mandelate. Supplied in bottles of 4 fl oz and 1 pint. This is a convenient dosage form for children for whom dosage must be adjusted on a weight basis. Also available as Mandelamine granules (1 gm and 0.5 gm) supplied in individual packets. Mandelamine granules produces an orange-flavored drink when dissolved in water according to directions.

M-GP-41-B/W

WARNER/CHILCOTT
Division, Warner-Lambert Company
Morris Plains, N.J. 07950

CAREER OPPORTUNITIES

UROLOGIST, age 35, available July, 1975, completed 3 years of general surgery residency prior to urology, seeking solo, association leading to partnership, or group practice in S. California. (213) 836-8781.

UROLOGIST, age 33, married, trained at major New York medical center seeking association leading to partnership or group practice; prefer New York City and vicinity, New Jersey, eastern Pennsylvania. (212) 727-8489.

UROLOGIST, age 31, married, university trained, will complete 4-year program June, 1975, well published, essay contest winner, desires association leading to partnership; prefer suburban New York or Boston. (212) 260-0713.

FMG completing training in urology, seeking senior year position to fulfill Board requirements. Box 741200.

WANTED, board-eligible or certified urologist, to associate with board-certified urologist in northeastern Pennsylvania. Private corporate practice, salary negotiable, fringe benefits included, early full partnership. Box 741201.

Page 1

U. S. POSTAL SERVICE
STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION
(Act of August 12, 1970: Section 3685, Title 39, United States Code)

SEE INSTRUCTIONS ON PAGE 2 (REVERSE)

1. TITLE OF PUBLICATION: UROLOGY
2. DATE OF FILING
3. FREQUENCY OF ISSUE: Monthly
4. LOCATION OF KNOWN OFFICE OF PUBLICATION *(Street, city, county, state, ZIP code) (Not printers)*: P.O.Box 643 - 55 North Maple Avenue - Ridgewood, Bergen, New Jersey07451
5. LOCATION OF THE HEADQUARTERS OR GENERAL BUSINESS OFFICES OF THE PUBLISHERS *(Not printers)*: Same as #4
6. NAMES AND ADDRESSES OF PUBLISHER, EDITOR, AND MANAGING EDITOR

PUBLISHER *(Name and address)*: Ronald P. Davis - P.O.Box 643 - 55 North Maple Ave., Ridgewood,N.J.07451
EDITOR *(Name and address)*: Pablo A. Morales,M.D.,Dept.of Urology-N.Y.Univ.Med.Center-N.Y.,N.Y.10016 566-1st Ave.
MANAGER EDITOR *(Name and address)*: Mary Politano - P.O.Box 643 - 55 North Maple Ave., Ridgewood, N.J. 07451

7. OWNER *(If owned by a corporation, its name and address must be stated and also immediately thereunder the names and addresses of stockholders owning or holding 1 percent or more of total amount of stock. If not owned by a corporation, the names and addresses of the individual owners must be given. If owned by a partnership or other unincorporated firm, its name and address, as well as that of each individual must be given.)*

NAME	ADDRESS
Ronald Park Davis, Inc. and Professional Medical Services Co.	P.O.Box 643 55 North Maple Avenue Ridgewood, N. J. 07451 P.O.Box 643-Ridgewood, N.J. 07451

8. KNOWN BONDHOLDERS, MORTGAGEES, AND OTHER SECURITY HOLDERS OWNING OR HOLDING 1 PERCENT OR MORE OF TOTAL AMOUNT OF BONDS, MORTGAGES OR OTHER SECURITIES *(If there are none, so state)*

NAME	ADDRESS

9. FOR OPTIONAL COMPLETION BY PUBLISHERS MAILING AT THE REGULAR RATES (Section 122.121, Postal Service Manual)

39 U. S. C. 3626 provides in pertinent part: "No person who would have been entitled to mail matter under former section 4359 of this title shall mail such matter at the rates provided under this subsection unless he files annually with the Postal Service a written request for permission to mail matter at such rates."

In accordance with the provisions of this statute, I hereby request permission to mail the publication named in Item 1 at the reduced postage rates presently authorized by 39 U. S. C. 3626.

(Signature and title of editor, publisher, business manager, or owner) Ronald P. Davis publisher

10. FOR COMPLETION BY NONPROFIT ORGANIZATIONS AUTHORIZED TO MAIL AT SPECIAL RATES *(Section 132.122, Postal Manual)*
(Check one)

The purpose, function, and nonprofit status of this organization and the exempt status for Federal income tax purposes: ☐ Have not changed during preceding 12 months ☐ Have changed during preceding 12 months *(If changed, publisher must submit explanation of change with this statement.)*

11. EXTENT AND NATURE OF CIRCULATION	AVERAGE NO. COPIES EACH ISSUE DURING PRECEDING 12 MONTHS	ACTUAL NUMBER OF COPIES OF SINGLE ISSUE PUBLISHED NEAREST TO FILING DATE
A. TOTAL NO. COPIES PRINTED *(Net Press Run)*	8,000	8,000
B. PAID CIRCULATION 1. SALES THROUGH DEALERS AND CARRIERS, STREET VENDORS AND COUNTER SALES		
2. MAIL SUBSCRIPTIONS		
C. TOTAL PAID CIRCULATION	4,625	5,226
D. FREE DISTRIBUTION BY MAIL, CARRIER OR OTHER MEANS 1. SAMPLES, COMPLIMENTARY, AND OTHER FREE COPIES	3,218	2,546
2. COPIES DISTRIBUTED TO NEWS AGENTS, BUT NOT SOLD		
E. TOTAL DISTRIBUTION *(Sum of C and D)*	7,843	7,772
F. OFFICE USE, LEFT-OVER, UNACCOUNTED, SPOILED AFTER PRINTING	157	228
G. TOTAL *(Sum of E & F—should equal net press run shown in A)*	8,000	8,000

I certify that the statements made by me above are correct and complete. ▶ *(Signature of editor, publisher, business manager, or owner)* Ronald P. Davis publisher

PS Form 3526 July 1971

As effective today as it was in 1938... Still keeping urine sterile.

Over the last 36 years, Mandelamine has provided one basic action. By converting to formaldehyde in acid urine, *it helps keep urine sterile.* And this provides one basic benefit—*to help prevent cystitis from recurring.* After ruling out complications, you can effectively use Mandelamine against both gram-positive and gram-negative organisms—without major organ toxicity or the development of resistance.

Mandelamine is effective for other reasons, too. It's well-tolerated for long-term use...with only an occasional skin rash or dysuria reported. It's economical...significantly less expensive tablet for tablet than any other branded methenamine salt at equivalent doses. And it's available in a variety of dosage forms that fit the needs of your patients...from pediatric to geriatric.

Mandelamine®
(methenamine mandelate)
To help prevent cystitis from recurring

Mandelamine® (methenamine mandelate)
Caution: Federal law prohibits dispensing without prescription.

Mandelamine, a urinary antibacterial agent, is the chemical combination of mandelic acid with methenamine.

Indications: Mandelamine (methenamine mandelate) is indicated for the suppression or elimination of bacteriuria associated with pyelonephritis, cystitis, and other chronic urinary tract infections; also for infected residual urine sometimes accompanying neurologic diseases. When used as recommended, Mandelamine is particularly suitable for long-term therapy because of its safety and because resistance to the nonspecific bactericidal action of formaldehyde does not develop. Pathogens resistant to other antibacterial agents may respond to Mandelamine because of the nonspecific effect of formaldehyde formed in an acid urine.

Contraindications: Contraindicated in renal insufficiency.

Precautions: Dysuria may occur (usually at higher than recommended dosage). This can be controlled by reducing the dosage and the acidification. When urine acidification is contraindicated or unattainable (as with some urea-splitting bacteria), the drug is not recommended.

Adverse Reaction: An occasional patient may experience gastrointestinal disturbance or a generalized skin rash.

Dosage and Management: The average adult dosage is 4 grams daily given as 1.0 gram after each meal and at bedtime. Children 6 to 12 should receive half the adult dose and children 5 years of age or under should receive 250 mg per 30 lb of body weight, four times daily. (See chart).

Mandelamine Dosages

Strength	Dosage Form	Dosage
1 gm	Mandelamine Tablets Mandelamine Granules (1.0 gm Packet)	Adults: 1 Tablet, q.i.d. 1 Packet, q.i.d.*
½ gm	Mandelamine Suspension Forte 500 mg/tsp	Children 6-12: 1 teaspoonful or 1 tablet, q.i.d. Adults: 2 teaspoonfuls or 2 tablets, q.i.d.
	Mandelamine ½ gm Tablets	
	Mandelamine Granules (0.5 gm Packets)	Adults: 2 Packets, q.i.d.*
¼ gm	Mandelamine Suspension 250 mg/tsp Mandelamine ¼ gm Tablets	Children 5 or under 1 teaspoonful or 1 tablet per 30 lb body weight, q.i.d.

*To be dissolved in 2-4 oz. of water immediately before using.

Since an acid urine is essential for antibacterial activity with maximum efficacy occurring at pH 5.5 or below, restriction of alkalinizing foods and medication is thus desirable. If testing of urine pH reveals the need, supplemental acidification should be given.

Supplied: 1 gm Tablets, 1.0 gm, purple enteric coated, bottles of 100 and 1000. ½ gm Tablets, 0.5 gm, brown enteric coated, bottles of 100 and 1000 tablets. ¼ gm Tablets, 0.25 gm, brown enteric coated, bottles of 100 and 1000 tablets.

Additional Dosage Forms: Mandelamine Suspension Forte containing 500 mg methenamine mandelate per teaspoonful; in bottles of 8 fl oz and 16 fl oz. This pink, cherry-flavored Suspension Forte is especially useful for pediatric patients and for those adults who cannot or will not swallow a tablet. Mandelamine Suspension—Each cream-colored coconut-flavored teaspoonful of Mandelamine Suspension contains 250 mg methenamine mandelate. Supplied in bottles of 4 fl oz and 1 pint. This is a convenient dosage form for children for whom dosage must be adjusted on a weight basis. Also available as Mandelamine granules (1 gm and 0.5 gm) supplied in individual packets. Mandelamine granules produces an orange-flavored drink when dissolved in water according to directions.

M-GP-41-B/W

WARNER/CHILCOTT
Division, Warner-Lambert Company
Morris Plains, N.J. 07950

CAREER OPPORTUNITIES

UROLOGIST, age 35, available July, 1975, completed 3 years of general surgery residency prior to urology, seeking solo, association leading to partnership, or group practice in S. California. (213) 836-8781.

UROLOGIST, age 33, married, trained at major New York medical center seeking association leading to partnership or group practice; prefer New York City and vicinity, New Jersey, eastern Pennsylvania. (212) 727-8489.

UROLOGIST, age 31, married, university trained, will complete 4-year program June, 1975, well published, essay contest winner, desires association leading to partnership; prefer suburban New York or Boston. (212) 260-0713.

FMG completing training in urology, seeking senior year position to fulfill Board requirements. Box 741200.

WANTED, board-eligible or certified urologist, to associate with board-certified urologist in northeastern Pennsylvania. Private corporate practice, salary negotiable, fringe benefits included, early full partnership. Box 741201.

Page 1

U. S. POSTAL SERVICE
STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION
(Act of August 12, 1970: Section 3685, Title 39, United States Code)

SEE INSTRUCTIONS ON PAGE 2 (REVERSE)

1. TITLE OF PUBLICATION: UROLOGY
2. DATE OF FILING:
3. FREQUENCY OF ISSUE: Monthly
4. LOCATION OF KNOWN OFFICE OF PUBLICATION *(Street, city, county, state, ZIP code) (Not printers)*: P.O.Box 643 - 55 North Maple Avenue - Ridgewood, Bergen, New Jersey07451
5. LOCATION OF THE HEADQUARTERS OR GENERAL BUSINESS OFFICES OF THE PUBLISHERS *(Not printers)*: Same as #4
6. NAMES AND ADDRESSES OF PUBLISHER, EDITOR, AND MANAGING EDITOR

PUBLISHER *(Name and address)*: Ronald P. Davis - P.O.Box 643 - 55 North Maple Ave., Ridgewood,N.J.07451
EDITOR *(Name and address)*: Pablo A. Morales,M.D.,Dept.of Urology-N.Y.Univ.Med.Center-N.Y.,N.Y.10016 566-1st Ave.
MANAGER EDITOR *(Name and address)*: Mary Politano - P.O.Box 643 - 55 North Maple Ave., Ridgewood, N.J. 07451

7. OWNER *(If owned by a corporation, its name and address must be stated and also immediately thereunder the names and addresses of stockholders owning or holding 1 percent or more of total amount of stock. If not owned by a corporation, the names and addresses of the individual owners must be given. If owned by a partnership or other unincorporated firm, its name and address, as well as that of each individual must be given.)*

NAME	ADDRESS
Ronald Park Davis, Inc. and Professional Medical Services Co.	P.O.Box 643 55 North Maple Avenue Ridgewood, N. J. 07451 P.O.Box 643-Ridgewood, N. J. 07451

8. KNOWN BONDHOLDERS, MORTGAGEES, AND OTHER SECURITY HOLDERS OWNING OR HOLDING 1 PERCENT OR MORE OF TOTAL AMOUNT OF BONDS, MORTGAGES OR OTHER SECURITIES *(If there are none, so state)*

NAME	ADDRESS

9. FOR OPTIONAL COMPLETION BY PUBLISHERS MAILING AT THE REGULAR RATES (Section 132.121, Postal Service Manual)

39 U. S. C. 3626 provides in pertinent part: "No person who would have been entitled to mail matter under former section 4359 of this title shall mail such matter at the rates provided under this subsection unless he files annually with the Postal Service a written request for permission to mail matter at such rates."

In accordance with the provisions of this statute, I hereby request permission to mail the publication named in item 1 at the reduced postage rates presently authorized by 39 U. S. C. 3626.

(Signature and title of editor, publisher, business manager, or owner) Ronald P. Davis publisher

10. FOR COMPLETION BY NONPROFIT ORGANIZATIONS AUTHORIZED TO MAIL AT SPECIAL RATES *(Section 132.122, Postal Manual)*
(Check one)

The purpose, function, and nonprofit status of this organization and the exempt status for Federal income tax purposes: ☐ Have not changed during preceding 12 months ☐ Have changed during preceding 12 months *(If changed, publisher must submit explanation of change with this statement.)*

11. EXTENT AND NATURE OF CIRCULATION	AVERAGE NO. COPIES EACH ISSUE DURING PRECEDING 12 MONTHS	ACTUAL NUMBER OF COPIES OF SINGLE ISSUE PUBLISHED NEAREST TO FILING DATE
A. TOTAL NO. COPIES PRINTED *(Net Press Run)*	8,000	8,000
B. PAID CIRCULATION 1. SALES THROUGH DEALERS AND CARRIERS, STREET VENDORS AND COUNTER SALES		
2. MAIL SUBSCRIPTIONS		
C. TOTAL PAID CIRCULATION	4,625	5,226
D. FREE DISTRIBUTION BY MAIL, CARRIER OR OTHER MEANS 1. SAMPLES, COMPLIMENTARY, AND OTHER FREE COPIES	3,218	2,546
2. COPIES DISTRIBUTED TO NEWS AGENTS, BUT NOT SOLD		
E. TOTAL DISTRIBUTION *(Sum of C and D)*	7,843	7,772
F. OFFICE USE, LEFT-OVER, UNACCOUNTED, SPOILED AFTER PRINTING	157	228
G. TOTAL *(Sum of E & F—should equal net press run shown in A)*	8,000	8,000

I certify that the statements made by me above are correct and complete. *(Signature of editor, publisher, business manager, or owner)* Ronald P. Davis publisher

PS Form 3526 July 1971

UROLOGIC MEETINGS

American Urological Association

May 11–15, 1975 – Fontainebleau Hotel, Miami Beach, Florida

May 16–20, 1976 – International Hotel, Las Vegas, Nevada

May 1–5, 1977 – Palmer House, Chicago, Illinois

May 21–25, 1978 – Washington Hilton, Washington, D.C.

Postgraduate Course in Uropathology

January 2 to 30, 1975
(9 sessions, Tuesdays and Thursdays, 2:30 to 6:30 P.M.) Columbia University College of Physicians and Surgeons, New York, New York

Under direction of Meyer M. Melicow, M.D., A. Uson, and Mrs. Maria Borowsky. Professor D. W. King will give introductory lecture, and Professor C. Pironi will discuss nephrology. Fee is $220, maximum class, 35.

For information contact:
Jose M. Ferrer, Jr., M.D., Associate Dean
630 West 168th Street
New York, New York 10032

Course in Genitourinary Pathology

January 20 to 24, 1975
Armed Forces Institute of Pathology
Washington, D.C.

Applicants must be qualified for American Board of examination in 1975 or Board-certified.
Urology Examination in 1975 or Board-certified.

For information contact:
The Director
Armed Forces Institute of Pathology
Washington, D.C. 20306

Postgraduate Seminar in Pediatric and Adult Urology

January 22 to 25, 1975
Miami Beach Hyatt House
Miami Beach, Florida

Registration fee is $125; applied for 17 credit hours, American Academy of Family Physicians.

For information contact:
Michael P. Small, M.D.
1200 N.W. 10th Avenue
Miami, Florida 33136, or
telephone (305) 324-0841.

Myelomeningocele: Habilitation and Rehabilitation

January 25, 1975
Shriner's Hospital for Crippled Children
San Francisco, California

Guest speakers: F. Brantley Scott, M.D.; Alexander, Cass, M.D.; and David Shurtleff, M.D.

For information contact:
Frank Hinman, M.D.
University of California School of Medicine
San Francisco, California 94143

Second Annual Course in Genitourinary Pathology

January 26, to 28, 1975
University of California, Irvine
California College of Medicine

For information contact:
Charles Paul, Dept. UNEX
University of California, Irvine
Irvine, California 92664

Ninth Ohio State University Urologic Outing: "How I Do It in Urology"

February 10 to 13, 1975
Kona Surf Hotel
Hawaii

For information contact:
Chester C. Winter, M.D.
Division of Urology
The Ohio State University
456 Clinic Drive
Columbus, Ohio 43210

The Harry Benjamin Fourth International Conference on Gender Identity

February 28 to March 2, 1975
Children's Hospital
Stanford, California

Program will provide a forum for interdisciplinary exchange of scientific information about patients who desire and are being considered for gender reidentification.

For information contact:
Donald Laub, M.D.
Division of Plastic Surgery, R213
Stanford University Medical Center
Stanford, California 94305

Postgraduate Course on Basic and Clinical Science Aspects of Male Reproduction

March 14 and 15, 1975
New York Medical College
New York, New York

Course will include anatomic, pathologic, neuroendocrinologic, physiologic, biochemical aspects of spermatogenesis, sperm transport, epididymal and vas physiology, prostate metabolism ejaculation, impotentia, effects of vasectomy, vasovasostomy, new scientific concepts in management of infertility, sperm transport in the female, and storage, analysis, and chemistry of semen.

For information contact:
Joseph E. Davis, M.D.
New York Medical College
Flower and Fifth Avenue Hospitals
New York, New York 10029

American Fertility Society

April 2 to 5, 1975
Century Plaza Hotel
Los Angeles, California

The American Fertility Society is sponsoring an essay contest for urology residents and fellows on some aspect of male human reproduction or sterilization. Original basic or clinical research is encouraged, but reviews are acceptable. An award of $1000 will be given to the prize-winning essay, which also will be presented at the annual meeting. Essays must be submitted by December 15, 1974.

For information and submission of essays:
Lawrence Dubin, M.D.
Clinical Professor of Urology
New York University
137 East 36th Street
New York, New York 10016

Thirteenth Annual Meeting of Association of Planned Parenthood Physicians

April 17 and 18, 1975
Century Plaza Hotel
Los Angeles, California

Features latest advances in family planning, including abortion, surgical contraception, and human sexuality. Abstracts of one-half to one and one-half pages are invited. *Note:* Five postgraduate courses will be given on April 16, prior to the clinical program.

For information contact:
Joseph E. Davis, M.D., Program Chairman
Association of Planned Parenthood Physicians
810 Seventh Avenue
New York, New York 10019

Urology: New Approaches

March 7 to 15 or 22, 1975
Innsbruck/St. Anton, Austria

(For detailed program see November issue, page 631.)

For information contact:
M. J. Vernon Smith, M.D.
The Institute for Continuing Education
P.O. Box 11083
2405 Westwood Avenue
Richmond, Virginia 23230

Thirteenth Annual Meeting of Society of University Urology Residents

May 7 to 10, 1975
Lowes Paradise Island Hotel and Villas
Paradise Island, Nassau, The Bahamas
Visiting professor: Victor Marshall, M.D., Professor and Chairman, Division of Urology, Cornell University.
Host professor: Victor A. Politano, M.D., Professor and Chairman, Department of Urology, University of Miami School of Medicine

For further information contact:
Martha D. Mazzarella, Administrative Assistant
Department of Urology
P.O. Box 520875
Miami, Florida 33152

American Association of Clinical Urologists

May 9 and 10, 1975
Fontainebleau Hotel
Miami Beach, Florida

For information contact:
Robert H. Bradley, Jr., M.D.
33 East Chestnut Hill Avenue
Philadelphia, Pennsylvania

Duke University Invitational Assembly for Advanced Urology

September 18 to 21, 1975
Pinehurst Hotel and Country Club
Pinehurst, North Carolina

The subject will be "Pediatric Urologic Problems" and guest faculty of outstanding pediatric urologists will be headed by J. Herbert Johnston, F.R.C.S., Liverpool, England. (Approximately 16 hours of Category I postgraduate education credit will be given.)

For information contact:
Virginia Jordan, Assembly Secretary
Box 3707, Duke University
Medical Center
Durham, North Carolina 27710.

INDEX TO ADVERTISERS

AMERICAN CYSTOSCOPE MAKERS, INC.
Microlens Optics 731-E

AYERST LABORATORIES
Thiosulfil 635-B,C,D

BARD CONSUMER PRODUCTS
Urinary Products 635-H

BURROUGHS-WELLCOME AND COMPANY, INC.
Empirin with Codeine ..... 4th Cover
Septra 665-B,C,D

EASTMAN KODAK COMPANY
X-Ray 731-F,G

EATON LABORATORIES
Furadantin Oral Suspension 702-E,F
Furadantin Tablets ..... 773-F, 3rd Cover

IVES LABORATORIES
Synalgos-DC 665-A

ELI LILLY AND COMPANY
Keflex 635-N

MERRILL-NATIONAL LABORATORIES
Hiprex 681-A

N. D. M. CORPORATION
Grounding Pad 681-H

THE PURDUE FREDERICK COMPANY
Betadine 731-A

ROCHE LABORATORIES
CEA 702-G,H,I
Gantrisin 702-A,B
Larocin 681-B-E

SMITH, KLINE & FRENCH LABORATORIES
Anspor 731-B,C,D

TBF INSTRUMENTS, INC.
Stone Disintegrator 702-D

U.S. VITAMIN
Doxy II 635-F

WARNER-CHILCOTT LABORATORIES
Mandelamine 793-B,C
Pyridium 635-L

WEBCON PHARMACEUTICALS
Cystospaz ..... 2nd Cover, 635-A
Hexalet 635-J,K

WYETH LABORATORIES
Bicillin/Wycillin 731-H,I,J
Phenergan Injection 681-F,G

ADVERTISING REPRESENTATIVES:
William V. Ferguson
Colleen Rodgers
Ronald Park Davis, Inc., Post Office Box 643
Ridgewood, New Jersey 07451
Telephone: (201) 444-8660

The nitrofurantoin with the assurance of Eaton bioavailability testing...competitively priced.

Furadantin®
(nitrofurantoin) 50 mg/100 mg tablets

INDICATIONS: Indicated for the treatment of pyelonephritis, pyelitis, and cystitis due to susceptible E. coli, enterococci, S. aureus (it is not indicated for the treatment of associated renal cortical or perinephric abscesses) and certain strains of Klebsiella-Aerobacter, Proteus and Pseudomonas.

CONTRAINDICATIONS: Anuria, oliguria, or significant impairment of renal function, infants under one month; pregnant patients at term, known hypersensitivity.

WARNINGS: May cause hemolytic anemia of the primaquine sensitivity type, apparently linked to a glucose-6-phosphate dehydrogenase deficiency. (Such patients should be closely observed while receiving nitrofurantoin.) Discontinue the drug at any sign of hemolysis. Hemolysis ceases on withdrawal. Superinfections (limited to the genitourinary tract) may occur, most commonly due to Pseudomonas. Safety not established during pregnancy and lactation, should not be used in women of childbearing potential unless the expected benefits outweigh the possible hazards.

PRECAUTIONS: Peripheral neuropathy may occur. A fatality has been reported. Predisposing conditions such as renal impairment, anemia, diabetes, electrolyte imbalance, vitamin B deficiency, and debilitating disease may enhance such occurrence.

ADVERSE REACTIONS:

Gastrointestinal Reactions—Anorexia, nausea, emesis are the most frequent reactions; less frequently, abdominal pain and diarrhea, rarely, hepatitis. This dose-related toxicity reaction can be minimized by reduction of dosage, especially in the female patient.

Hypersensitivity Reactions—Pulmonary sensitivity reactions, which can be acute, subacute, or chronic. Acute reaction is commonly manifested by fever, chills, cough, chest pain, dyspnea, pulmonary infiltration with consolidation or pleural effusion on X-ray and eosinophilia. The acute reactions usually occur within the first week of treatment and resolve with cessation of the drug therapy.

Subacute or chronic pulmonary reaction is associated with prolonged therapy. Insidious onset of malaise, dyspnea on exertion, cough, altered pulmonary function, and roentgenographic and histologic findings of diffuse interstitial pneumonitis or fibrosis or both are common manifestations. Impaired pulmonary function may result even after cessation of the drug therapy.

Dermatologic Reactions—Maculopapular, erythematous, or eczematous eruption, pruritus, urticaria, and angioedema.

Other Sensitivity Reactions—Anaphylaxis, asthmatic attack in patients with history of asthma, cholestatic jaundice, drug fever and arthralgia.

Hematologic Reactions—Hemolytic anemia, granulocytopenia, eosinophilia, and megaloblastic anemia. Return of the blood picture to normal has followed cessation of therapy.

Neurological Reactions—Peripheral neuropathy, headache, dizziness, nystagmus, and drowsiness.

Miscellaneous Reactions—Transient alopecia.

SUPPLIED: FURADANTIN (nitrofurantoin) is supplied as round, yellow, bisected imprinted tablets of 50 mg (coded "Eaton 036") and 100 mg (coded "Eaton 037") in bottles of 25, 100 and 500 tablets. FURADANTIN Tablets are also available in hospital unit-dose packages, strip-packaged in boxes of 100.

FURADANTIN (nitrofurantoin) Oral Suspension, 25 mg per 5 cc. tsp., in bottles of 60 and 473 cc.

® Originators and Developers of the Nitrofurans
EATON LABORATORIES
division of Morton-Norwich Products, Inc.
Norwich, N.Y. 13815

Can you be sure of bioavailability when you prescribe nitrofurantoin?

Nitrofurantoin is one of several drugs with bioavailability problems, according to recent testimony presented at a Senate hearing.

Furthermore, a government-appointed panel of experts has concluded that the problem of bioinequivalence "is a real one" and that existing standards and controls cannot assure bioequivalence. It settles a long-standing debate concerning assigned equivalency of seemingly identical prescription medicines.

You can be sure of bioavailability when you prescribe Furadantin® (nitrofurantoin)!

During more than 20 years of manufacturing Furadantin, Eaton has constantly upgraded its high production and testing standards. Each batch of bulk nitrofurantoin is subjected to 16 man-days of testing, and Eaton quality control has established more precise and complete testing than that demanded by U.S.P. requirements.

But beyond our high *in vitro* standards, Eaton's bioavailability standards are based on *in vivo* testing in humans, and not merely on laboratory or animal tests. Thus, when you prescribe Furadantin, you can be sure that your patient gets the medication you expect him to get. Such certainty is unavailable with generic nitrofurantoin that has not been subjected to the same *in vivo* and *in vitro* testing.

Over 20 years of experience... more than 54,000,000 courses of therapy stand behind

Furadantin®

(nitrofurantoin) 50 mg/100 mg tablets

The nitrofurantoin with the assurance of Eaton bioavailability testing...competitively priced.

Please see facing page for brief summary of prescribing information.

HERE

After surgery

Wherever it hurts, Empirin Compound with Codeine usually provides the relief needed.

HERE

Renal calculus



In general, only pain so severe that it requires morphine is beyond the scope of Empirin Compound with Codeine.

prescribing convenience: up to 5 refills in 6 months, at your discretion (unless restricted by state law); by telephone order in many states.

Empirin Compound with Codeine **No. 3,** codeine phosphate* 32.4 mg. (gr. ½); **No. 4,** codeine phosphate* 64.8 mg. (gr. 1). *Warning—may be habit-forming. Each tablet also contains: aspirin gr. 3½, phenacetin gr. 2½, caffeine gr. ½.

Wellcome / **Burroughs Wellcome Co.**
Research Triangle Park
North Carolina 27709

WHEREVER IT HURTS



EMPIRIN® COMPOUND c̄ CODEINE

#3, codeine phosphate* (32.4 mg.), gr. ½
#4, codeine phosphate* (64.8 mg.), gr. 1